LivaNova price target raised to $72 from $70 at Stifel

Stifel raised the firm’s price target on LivaNova to $72 from $70 and keeps a Buy rating on the shares. When LivaNova reports 2Q24 earnings on July 31, the firm also expects the company to share an important depression program outlook update as new CEO Vladimir Makatsaria puts his “mark” on the company’s go-forward strategy, the analyst tells investors in a preview note.With shares down about 10% since the June 6 RECOVER trial top-line-miss, the firm thinks “investors should revisit the LIVN story,” the analyst added.